Biotech Values

[mcbio]

But more immediate competition is Avastin, which met primary endpoint PFS in PROC regardless of folate receptor from a ph3 study earlier this year.

My understanding is that it was actually PSOC (platinum-sensitive ovarian cancer), and not PROC (platinum-resistant ovarian cancer), which is the more dire patient population that MRK/ECYT are targeting with vintafolide.